Asset Details
Do you wish to reserve the book?
Serum C‐Terminal Agrin Fragment With Acute and Long‐Term Exercise and Angiotensin II Type I Receptor Blockade
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Serum C‐Terminal Agrin Fragment With Acute and Long‐Term Exercise and Angiotensin II Type I Receptor Blockade
Do you wish to request the book?
Serum C‐Terminal Agrin Fragment With Acute and Long‐Term Exercise and Angiotensin II Type I Receptor Blockade
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Serum C‐Terminal Agrin Fragment With Acute and Long‐Term Exercise and Angiotensin II Type I Receptor Blockade
2025
Overview
Background Sarcopenia represents a major clinical and societal challenge facing rapidly aging populations. Accessible and specific biomarkers represent valuable tools, both in diagnosis and assessing the efficacy of therapeutic interventions. C‐terminal agrin fragment (CAF) is the most commonly used blood‐based biomarker of neuromuscular junction degradation in aging, inactivity and disease, but large unexplained interindividual variation exists, limiting its diagnostic and prognostic value. Exercise and medication may explain some of this variation. The aim of this study was to investigate the influence of a single bout (1EX) or 48 bouts (48EX) of heavy resistance exercise (EX), with or without angiotensin II type I receptor blocker (losartan (LOS)) supplementation, on serum CAF levels in healthy older men. Methods Eighty‐three healthy, normotensive older men were enrolled in one of two randomized placebo (PLA) controlled trials. 1EX: 25 participants (EX ± LOS), with a mean age of 70 ± 7 years, had blood drawn before and after (4.5 h, Days 1, 4 and 7) a single bout of unilateral heavy resistance exercise of the quadriceps muscles. 48EX: at baseline, and after 8 and 16 weeks of a progressive heavy resistance exercise program, 58 participants (LOS‐EX, n = 20; LOS‐SED, n = 20; PLA‐EX, n = 18), with a mean age of 72 ± 5 years, had blood drawn, and specific force (strength per unit mass) was measured by dynamometer and magnetic resonance imaging of the quadriceps muscles. Serum CAF was measured by ELISA. Results At baseline, CAF showed weak correlations with age and leg lean mass (both R2 = 0.07, p < 0.05). With 48EX, specific force increased in both EX groups (LOS‐EX + PLA‐EX) by 13%–14% at 8 weeks and 14%–17% at 16 weeks (p < 0.0001), with no change in LOS‐SED (p > 0.05), confirming the efficacy of the 48EX program. Serum CAF increased in LOS‐EX and LOS‐SED by 4%–7% at 8 weeks and 7%–9% at 16 weeks (p < 0.005) respectively, with no change in PLA‐EX (p > 0.05). 1EX reduced CAF by 8% 1 day postexercise (p < 0.05), with no correlation to circulating creatine kinase levels (p > 0.05), a marker of muscle damage. Conclusions Serum CAF was unaffected by 16 weeks of EX but increased by LOS supplementation. 1EX, performed with one leg, acutely lowered serum CAF, albeit with substantial interindividual variability. These findings collectively identify novel stimuli of serum CAF turnover—drug interaction and time from last exercise bout to blood sampling. These findings add value to CAF as a neuromuscular biomarker and highlight important experimental design aspects for future clinical studies.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
